Kibow Biotech has announced the availability of the first proprietary dietary supplement for kidney health in India. The launch coincides with the World Kidney Day observed on March 13 annually. Now the company is in discussions with the pharma marketing and sales in India.
The product which is sold in the US for $45 for 60 capsules would be made far more affordable for the Indian market. Renadyl is expected to benefit the 1.5 million kidney patients in the country. Its key feature is to reduce the toxins effects and delay the progression of kidney failure, said Dr Natarajan Ranganathan, managing director, Kibow Biotech here at a press conclave.
Further the announcement comes close on the heels of the Indian Patent Appellate Board ruling upholding Kibow’s product patent for Renadyl.
The product is an outcome of 12 years of extensive research and development. Renadyl is an oral proprietary dietary supplement which has been scientifically formulated and clinically tested to help support blood stream concentrations of nitrogenous waste metabolites in the bowel and also stabilise the healthy gut flora.
“Our probiotic formulations of S. thermophilus (KB19,) Lacidophilus (KB27) and B longum (KB 31) targets at metabolising nitrogenous wastes that scatters from the blood stream into the bowel. These naturally occurring beneficial microbes have high affinity to metabolise and thus consume the targeted nitrogenous waste products. Now this is known as the Uremic Toxin Reduction Technology or Enteric Dialysis which is extremely helpful for patients with chronic kidney failure. The company has performed three clinical trials globally to demonstrate the product for a pharmaceutical-like validation. In India, with the new clause on patient compensation for even a placebo drug’s adverse reaction, issued by the Union government’s health and family welfare ministry, dissuaded it from conducting human studies here. But the company is still open for a physician study on a limited pool of patients to prove its efficacy even though dietary supplements do not mandate clinical trials in India”, said Dr. Ranganathan.
The mechanism of Renadyl takes place in the large intestines. As the kidney function slows down, nitrogenous waste builds up in the blood. The probiotic microbes begin to multiply and this in turn allows greater diffusion of nitrogenous water. However, Renadyl cannot replace dialysis because it is not a drug and only maintains the healthy function of the kidneys, he said.
Moreover, probiotics can be taken 2 to 3 hours after antibiotic treatment. In the case of Renadyl, its use will not interfere with the effectiveness of antibiotics if used occasionally.
At Kibow, there is extensive R&D being undertaken for several pre and probiotics. The company is also seeking direct investments and is scouting for collaborations to rapidly expand its direct consumer marketing and sales globally.
